Table 1. Open in new tab Aminoglycoside...

Antimicrobial	Breakpoint (Susceptible/Resistant) in mg/L
Plazomicin	≤2/≥8	NA	≤2/≥8	NA	≤4/≥8
Amikacin	≤4/≥16	≤16/≥ 64^a	≤16/≥64^a	≤8/≥ 16	≤4/≥8
Gentamicin	≤2/≥8	≤4/≥ 16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4
Tobramycin	≤2/≥8	≤4/≥16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4

Antimicrobial	Breakpoint (Susceptible/Resistant) in mg/L
Plazomicin	≤2/≥8	NA	≤2/≥8	NA	≤4/≥8
Amikacin	≤4/≥16	≤16/≥ 64^a	≤16/≥64^a	≤8/≥ 16	≤4/≥8
Gentamicin	≤2/≥8	≤4/≥ 16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4
Tobramycin	≤2/≥8	≤4/≥16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4

Table 1.

Aminoglycoside Breakpoints Published by CLSI 2023, CLSI 2022, the US FDA, EUCAST, and USCAST

Antimicrobial	Breakpoint (Susceptible/Resistant) in mg/L
	CLSI (2023)	CLSI (2022)	US FDA^a	EUCAST	USCAST
Plazomicin	≤2/≥8	NA	≤2/≥8	NA	≤4/≥8
Amikacin	≤4/≥16	≤16/≥ 64^a	≤16/≥64^a	≤8/≥ 16	≤4/≥8
Gentamicin	≤2/≥8	≤4/≥ 16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4
Tobramycin	≤2/≥8	≤4/≥16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4

Antimicrobial	Breakpoint (Susceptible/Resistant) in mg/L
	CLSI (2023)	CLSI (2022)	US FDA^a	EUCAST	USCAST
Plazomicin	≤2/≥8	NA	≤2/≥8	NA	≤4/≥8
Amikacin	≤4/≥16	≤16/≥ 64^a	≤16/≥64^a	≤8/≥ 16	≤4/≥8
Gentamicin	≤2/≥8	≤4/≥ 16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4
Tobramycin	≤2/≥8	≤4/≥16^a	≤4/≥16^a	≤2/≥ 4	≤2/≥4

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; NA, not applicable; US FDA, United States Food and Drug Administration; USCAST, United States Committee on Antimicrobial Susceptibility Testing.

US FDA recognized the CLSI M100 (2022) standard for amikacin, gentamicin, and tobramycin [6].

This Feature Is Available To Subscribers Only